Aug. 9 at 3:30 PM
$PRME I am adding to my short here:
-The rise in June and July had no fundamental basis or change in the company's news or operations. It was purely technical and will reverse to the mean below
$2.
-Extremely early pre-clinical stages means the risk of failure is substantial in larger scale trials.
-Check their operating losses = massive every quarter.
-Cash burn is too large and clearly many dilution rounds are being used at the expense of current investors.
-Initiation of phase 1 trial is not until 2026 and data not until 2027. We all know how many bad events, including more dilutions will happen by then.
-High short interest = consensus of lower stock price expected.
